Low-level laser prevents doxorubicin-induced skeletal muscle atrophy by modulating AMPK/SIRT1/PCG-1α-mediated mitochondrial function, apoptosis and up-regulation of pro-inflammatory responses

BACKGROUND: Doxorubicin (Dox) is a widely used anthracycline drug to treat cancer, yet numerous adverse effects influencing different organs may offset the treatment outcome, which in turn affects the patient’s quality of life. Low-level lasers (LLLs) have resulted in several novel indications in ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Hsiu-Chung, Chu, Pei-Ming, Huang, Yu-Ting, Cheng, Hui-Ching, Chou, Wan-Ching, Yang, Hsin-Lun, Chen, Hsiu-I., Tsai, Kun-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650328/
https://www.ncbi.nlm.nih.gov/pubmed/34876217
http://dx.doi.org/10.1186/s13578-021-00719-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650328/
https://www.ncbi.nlm.nih.gov/pubmed/34876217
http://dx.doi.org/10.1186/s13578-021-00719-w

Ejemplares similares